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A B S T R A C T
Background
Pulse oximetry could contribute to the evaluation of fetal well-being during labour.
Objectives
To compare the effectiveness and safety of fetal pulse oximetry with conventional surveillance techniques.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (May 2010), MEDLINE (1994 to May 2010), EMBASE
(1994 to May 2010), Current Contents (1994 to May 2010) and contacted experts in the field.
Selection criteria
All published and unpublished randomised controlled trials that compared maternal and fetal outcomes when fetal pulse oximetry was
used in labour, with or without concurrent use of conventional fetal surveillance, compared with using cardiotocography (CTG) alone.
Data collection and analysis
At least two independent authors performed data extraction.We performed analyses on an intention-to-treat basis. We sought additional
information from the investigators of three of the reported trials.
Main results
We included six published trials comparing fetal pulse oximetry and CTG with CTG alone (or when fetal pulse oximetry values were
blinded). The published trials, with some unpublished data, reported on a total of 7654 pregnancies. Differing entry criteria necessitated
separate analyses, rather than meta-analysis of all trials.
Systematic review of four trials from 34 weeks not requiring fetal blood sampling prior to study entry showed no significant differences
in the overall caesarean section rate between those monitored with fetal oximetry and those not monitored with fetal pulse oximetry or
for whom the fetal pulse oximetry results were masked (risk ratio (RR) 0.99, 95% confidence intervals (CI) 0.86 to 1.13, n = 4008).
Neonatal seizures and neonatal encephalopathy were rare. No studies reported details of assessment of long-term disability.
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There was a statistically significant decrease in caesarean section for nonreassuring fetal status in the fetal pulse oximetry plus CTG
group compared to the CTG group, gestation from 34 weeks (RR 0.65, 95% CI 0.46 to 0.90). There was no statistically significant
difference in caesarean section for dystocia when fetal pulse oximetry was added to CTG monitoring, compared with CTGmonitoring
alone, although the incidence rates varied between the trials.
Authors’ conclusions
The data provide limited support for the use of fetal pulse oximetry when used in the presence of a nonreassuring CTG, to reduce
caesarean section for nonreassuring fetal status. The addition of fetal pulse oximetry does not reduce overall caesarean section rates. A
better method to evaluate fetal well-being in labour is required.
P L A I N L A N G U A G E S U M M A R Y
Fetal pulse oximetry for fetal assessment in labour
Using fetal pulse oximetry to assess the baby’s well-being during labour does not change overall caesarean section rates.
During labour, the well-being of the baby can be assessed intermittently using a Pinard stethoscope or hand held monitor, or con-
tinuously using cardiotocography (CTG, sometimes called electronic fetal monitoring, EFM) or assessing the baby’s condition with
an electrocardiogram (ECG). There are also additional tests that can be used if the baby is thought to be getting short of oxygen,
like testing the baby’s blood in a sample taken from the baby’s head or bottom. A new method, fetal pulse oximetry, measures how
much oxygen the baby’s blood is carrying. It uses a probe that sits inside the vagina during labour. The probe is said not to inhibit the
woman’s mobility during labour. This review looked at fetal pulse oximetry and only found trials that used it in conjunction with a
CTG and compared the combined use with CTG alone. The review identified six trials involving 7654 women. Fetal pulse oximetry
plus CTG showed no difference in caesarean section rates overall, nor any difference in the mother’s or newborn’s health, compared
with CTG alone. If there was concern about the baby’s well-being before the fetal pulse oximetry probe was placed, the use of fetal
pulse oximetry reduced caesarean sections performed for the baby’s well-being. In one of the trials, the company making the fetal pulse
oximetry machines provided some funding. Further trials may be helpful.
B A C K G R O U N D
Cardiotocography (CTG) was introduced in the 1960s with the
aim of improving neonatal outcomes by improving intrapartum
fetal surveillance. Fetal heart rate patterns may be classified as re-
assuring, nonreassuring or abnormal, based on the rate, variability
and decelerations, and to some extent comparing these to the tim-
ing of uterine contractions. There are several published guidelines
for the interpretation of these patterns (for example, RANZCOG
2002; RCOG 2001). Reassuring patterns require no specific ac-
tion. Nonreassuring patterns occur in about 15% of labours mon-
itored by CTG (Umstad 1993) and may prompt clinical actions
ranging from simple manoeuvres, such as a change of maternal
position, through to expedited birth of the baby (vacuum, for-
ceps, caesarean section). Abnormal patterns usually prompt ex-
pedited birth with the aim of preventing or minimising hypoxia
in the fetus. The positive predictive value of CTG for adverse
outcome is low and the negative predictive value high (Umstad
1993), although this is improving with computerised interpreta-
tion of CTGs (Strachan 2001). Thus, while a normal CTG usu-
ally indicates reassuring fetal status, a nonreassuring or abnormal
CTG does not necessarily equate with ’fetal distress’. These fea-
tures, combined with marked inter-observer variation in CTG in-
terpretation by midwives (Devane 2005) and doctors (Palomaki
2006), result in variable but inappropriately high operative de-
livery rates for nonreassuring fetal status in many hospitals. Elec-
tronic fetal monitoring rapidly gained widespread acceptance for
monitoring the fetal heart rate during labour, but it was not until
the 1970s that randomised controlled trials were conducted to as-
sess the benefits of this technology. A Cochrane systematic review
found that the use of electronic monitoring increased the odds of
having a caesarean section, compared to intermittent auscultation
of the fetal heart (Alfirevic 2006). Despite these shortcomings,
cardiotocography remains a widely used means of assessing fetal
well-being during labour. One conclusion of the systematic review
of CTG monitoring was to consider how to best convey the un-
certainty of the benefits of such monitoring to enable women to
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make an informed choice, while not compromising labour nor-
mality (Alfirevic 2006). The Royal College of Obstetricians and
Gynaecologists (RCOG 2001) suggested that, as for all aspects of
care, the woman herself should be involved in decision-making for
choice of fetal monitoring, with adequate access to evidence-based
information; and recommended that electronic monitoring be of-
fered where there is an increased risk of perinatal death, neonatal
encephalopathy or cerebral palsy, and during labours induced or
augmented by oxytocin.
Once a nonreassuring fetal heart rate pattern has been identified, a
number of additional assessments of fetal well-being may be con-
sidered. These do not replace the CTG, but are usually used as
complementary to it, either intermittently or continuously. One
example is fetal scalp blood sampling for pH or lactate analysis. A
low pH (for example, less than 7.20) or a high lactate (for example
greater than 4.8 mmol/L) may be considered abnormal (Kruger
1999). The addition of fetal scalp blood sampling to standard elec-
tronicmonitoring reduces the odds for caesarean section, although
the odds are not significantly different compared to intermittent
auscultation of the fetal heart (Alfirevic 2006). A Cochrane sys-
tematic review of the addition of fetal electrocardiogrammonitor-
ing reported no difference in overall caesarean section rate when
compared to electronic monitoring only (Neilson 2006).
Fetal pulse oximetry is a new technology aimed at improving
the accuracy of the evaluation of fetal well-being during labour
(Colditz 1999; East 2007). It is generally reserved for use when
a nonreassuring CTG has been recorded, to assist in identify-
ing those fetuses that may benefit from further intervention (East
2002; East 2008) and as an adjunct to, rather than replacement of,
the CTGmonitor. This method has two potential advantages over
conventional fetal heart rate monitoring: (i) it directly measures
the proportion of haemoglobin that is carrying oxygen: thus, oxy-
genation, the primary variable underlying the tissue damaging ef-
fects of hypoxia/ischaemia is being monitored; and (ii) it relies on
an established, safe, noninvasive, widely-used technology found in
every modern intensive care unit and operating theatre. A variety
of fetal pulse oximetry sensors has been studied. These are placed
during a vaginal examination to attach to the top of the fetal head
by suction (Arikan 2000) or clip (Knitza 2004), lie against the
fetal temple or cheek (Mallinckrodt 2000; Nellcor 2004), or to lie
along the fetal back (OB Scientific 2002). The sensor remains in
situ and fetal pulse oximetry values are recorded for approximately
81% of the monitoring time (East 1997). Results of animal and
human research suggest that when using sensors calibrated for the
fetal environment, fetal oximetry values greater than or equal to
30% are considered reassuring, even when the CTG is nonreas-
suring, while values less than 30% warrant consideration of in-
terventions, ranging from maternal position change, through to
urgent birth via caesarean section (Kuhnert 1998; Nijland 1995;
Seelbach-Gobel 1999). One manufacturer recommends this tech-
nology for singleton pregnancies only (Nellcor 2004). Considera-
tion for monitoring multiple pregnancies by monitoring the first
fetus during labour, then the second or subsequent fetuses follow-
ing birth of the preceding fetusmay be possible.Womenhave rated
their experience with fetal oximetry during observational studies.
One survey included questions about the woman’s perceived level
of comfort during sensor placement, mobility with the sensor in
place and ongoing comfort with the sensor in place: these factors
were all rated favourably by the women (East 1996). Arikan 1998
reported that the majority of women did not consider that a fetal
oximetry sensor restricted their movement during labour.
The value of any fetal monitoring system during labour, including
the CTG or any additional surveillance, is usually expressed by
its ability to predict which fetuses are hypoxic or acidotic. Mea-
sures of this may include umbilical cord blood gases (including
base excess values less than or equal to 12 mmol/L and pH val-
ues less than 7.00 (Sehdev 1997), or less than 7.10 (Arikan 2000)
or lactate values; or clinical outcomes including Apgar scores (an
assessment of neonatal condition shortly after birth, usually at
one and five minutes: Apgar scores of less than seven at five min-
utes or later are nonspecific but may be associated with hypoxia
(MacLennan 1999; Sehdev 1997)); or abnormal neurological sta-
tus of the baby, possibly caused by lack of oxygen or blood supply
(hypoxic-ischaemic encephalopathy), or both. Other outcomes of
interest may include fetal/maternal infections, for example of the
membranes (chorioamnionitis), or the uterine lining (endometri-
tis). Interventions resulting from such tests are also important.
For example, it is important to note not only overall modes of
birth following different forms of monitoring, but also specific
interventions, such as operative birth (vacuum, forceps and cae-
sarean section) for the indication of nonreassuring fetal status,
since nonreassuring fetal status is what the monitoring is intended
to discern. In the longer term, such interventions may also impact
on future pregnancies. For example, the likelihood of a successful
vaginal birth after caesarean (VBAC) in a subsequent pregnancy
is improved for women whose previous caesarean was performed
for the indication of nonreassuring fetal status, compared with
those where the previous caesarean was performed for dystocia
(Grinstead 2004; Shipp 2000). Successful VBAC in a subsequent
pregnancy will also have economic benefits, with vaginal births
costing the health system considerably less than caesarean sections
(Henderson 2001; Petrou 2002).
This review was undertaken to evaluate the clinical effectiveness
and safety of fetal pulse oximetry to assess fetal well-being in labour.
O B J E C T I V E S
To compare the effectiveness and safety of fetal intrapartum pulse
oximetry with conventional fetal surveillance techniques, using
the results of randomised controlled trials.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished randomised and quasi-randomised
trials with reported data that compared maternal and fetal/neona-
tal/infant outcomes when fetal pulse oximetry was used in labour,
with or without concurrent use of conventional fetal surveillance,
compared with the use of conventional fetal surveillance tech-
niques alone.
Types of participants
Women in labour with a live baby where fetal monitoring is clin-
ically indicated.
Types of interventions
Use of fetal pulse oximetry compared with not using fetal pulse
oximetry, with or without concurrent use of conventional fetal
monitoring (fetal heart rate monitoring by intermittent auscul-
tation, intermittent/continuous cardiotocography, or fetal blood
sampling for blood gas analysis).
Types of outcome measures
Primary outcomes
(1) Caesarean section
(2) Hypoxic-ischaemic encephalopathy
(3) Neonatal seizures
(4) Long-term neurodevelopmental outcome
Secondary outcomes
Maternal
(5) Caesarean section for nonreassuring fetal status
(6) Caesarean section for dystocia (added since the protocol and
original review were first published)
(7) Overall operative delivery (caesarean section, forceps, vacuum
extraction) for all indications
(8) Overall operative delivery (caesarean section, forceps, vacuum
extraction) for nonreassuring fetal status
(9) Use of intrapartum antibiotics
(10) Overall antibiotic use
(11) Intrapartum haemorrhage
(12) Postpartum haemorrhage
(13) Chorioamnionitis
(14) Endometritis (added since the protocol was first published)
(15) Uterine rupture
(16) Length of hospital stay
(17) Satisfaction with labour
(18) Satisfaction with fetal monitoring in labour
(19) Death
Fetal/neonatal
(20) Skin trauma
(21) Apgar scores less than four at five minutes
(22) Apgar scores less than seven at five minutes
(23) Umbilical arterial pH less than 7.10
(24) Umbilical arterial base excess less than -12
(25) Admission to neonatal intensive care unit
(26) Length of hospital stay
(27) Death
(28) Death, hypoxic-ischaemic encephalopathy, or both
(29) Death, seizures, or both
(30) Death, long-term neurodevelopmental problem, or both
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (May
2010).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the edito-
rial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
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In addition, we searched MEDLINE (1994 to May 2010), EM-
BASE (1994 to May 2010) and Current Contents (1994 to May
2010): searches were conducted from 1994 onwards as pulse
oximetry technology calibrated for the fetal environment has only
been available since 1994. See:Appendix 2 for search strategy used.
Searching other resources
We also sought ongoing and unpublished trials by contacting ex-
perts in the field.
We did not apply any language restrictions.
Data collection and analysis
For the methods used when assessing the trials identified in the
previous version of this review, see Appendix 1.
For this update we used the following methods when assessing
the reports identified by the updated search (Caliskan 2009; an
economic analysis of East 2006; a conference abstract by Prieto
2008; and an abstract and published sub-study by Rouse, from
the Bloom 2006 trial).
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies we identified as a result of the search strategy.
We planned to resolve any disagreement through discussion or, if
required, we planned to consult a third person.
Data extraction and management
Wedesigned a form to extract data. For eligible studies, two review
authors extracted the data using the agreed form. We planned to
resolve discrepancies through discussionor, if required,we planned
to consult a third person. We entered data into Review Manager
software (RevMan 2008) and checked for accuracy.
When information regarding any of the above were unclear, we
planned to attempt contact with authors of the original reports to
provide further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2009). We planned
to resolve any disagreement by discussion or by involving a third
assessor.
(1) Sequence generation (checking for possible selection
bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• adequate (any truly random process, e.g. random number
table; computer random number generator),
• inadequate (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number) or,
• unclear.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to conceal
the allocation sequence and determine whether intervention allo-
cation could have been foreseen in advance of, or during, recruit-
ment, or changed after assignment.
We assessed the methods as:
• adequate (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• inadequate (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear.
(3) Blinding (checking for possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if theywere blinded, or if we judged that the
lack of blinding could not have affected the results. We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• adequate, inadequate or unclear for participants;
• adequate, inadequate or unclear for personnel;
• adequate, inadequate or unclear for outcome assessors.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we planned to re-include missing data in the
analyses which we undertook. We assessed methods as:
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• adequate;
• inadequate;
• unclear.
(5) Selective reporting bias
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• adequate (where it was clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review had been reported);
• inadequate (where not all the study’s pre-specified outcomes
had been reported; one or more reported primary outcomes were
not pre-specified; outcomes of interest were reported
incompletely and so cannot be used; study failed to include
results of a key outcome that would have been expected to have
been reported);
• unclear.
(6) Other sources of bias
Weplanned to describe for each included study any important
concerns about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• yes;
• no;
• unclear.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2009). With reference to (1) to (6) above, we assessed
the likely magnitude and direction of the bias and whether we
considered it was likely to impact on the findings. We planned
to explore the impact of the level of bias through undertaking
sensitivity analyses - see Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we used the mean difference if outcomes
were measured in the same way between trials. We planned to use
the standardised mean difference to combine trials that measure
the same outcome, but used different methods.
Unit of analysis issues
Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses
along with individually randomised trials. We planned to adjust
their sample sizes or standard errors using the methods described
in theHandbookHiggins 2009 using an estimate of the intracluster
correlation co-efficient (ICC) derived from the trial (if possible),
from a similar trial or from a study of a similar population. If
we had used ICCs from other sources, we would have reported
this and conducted sensitivity analyses to investigate the effect of
variation in the ICC. If we had identified both cluster-randomised
trials and individually-randomised trials, we planned to synthesise
the relevant information. We would have considered it reasonable
to combine the results from both if there was little heterogeneity
between the study designs and the interaction between the effect of
intervention and the choice of randomisation unit was considered
to be unlikely.
We also planned to acknowledge heterogeneity in the randomisa-
tion unit and perform a sensitivity analysis to investigate the ef-
fects of the randomisation unit.
Crossover trials
We planned to exclude crossover trials in this review, as they are
not an appropriate study design for assessment of the effects of
fetal monitoring during labour.
Dealing with missing data
For included studies, we noted levels of attrition. We planned to
explore the impact of including studies with high levels of missing
data in the overall assessment of treatment effect by using sensi-
tivity analysis.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and all partici-
pants were analysed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial was the number
randomised minus any participants whose outcomes were known
to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T2, I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if T2 was greater than zero and either I2 was greater than
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30% or there was a low P-value (less than 0.10) in the Chi² test
for heterogeneity.
Assessment of reporting biases
If there had been 10 or more studies in the meta-analysis we
planned to investigate reporting biases (such as publication bias)
using funnel plots. We planned to assess funnel plot asymmetry
visually, and use formal tests for funnel plot asymmetry. For con-
tinuous outcomes we planned to use the test proposed by Egger
1997, and for dichotomous outcomes we planned to use the test
proposed by Harbord 2006. If we detected asymmetry in any of
these tests or by a visual assessment, we planned to perform ex-
ploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2008).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
examined the same intervention, and the trials’ populations and
methods were judged sufficiently similar. If there was clinical het-
erogeneity sufficient to expect that the underlying treatment ef-
fects differ between trials, or if substantial statistical heterogeneity
was detected, we used random-effects meta-analysis to produce
an overall summary if an average treatment effect across trials was
considered clinically meaningful. The random-effects summary
was treated as the average range of possible treatment effects and
we discussed the clinical implications of treatment effects differing
between trials. If the average treatment effect was not clinically
meaningful we did not combine trials (see Subgroup analysis and
investigation of heterogeneity) .
If we used random-effects analyses, we presented the results as the
average treatment effect with its 95% confidence interval, and the
estimates of T2 and I2.
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we investigated it using
subgroup analyses and sensitivity analyses.
We planned to carry out the following subgroup analyses.
Fetal pulse oximetry compared with:
1. fetal heart rate monitoring by:
• intermittent auscultation;
• intermittent cardiotocography;
• continuous cardiotocography;
• continuous cardiotocography and fetal scalp stimulation;
• continuous cardiotocography and fetal electrocardiogram
(ECG) analysis (ST segment);
• continuous cardiotocography and fetal ECG analysis (PR
interval); and
2. fetal blood sampling for blood gas analysis.
Several trials indicated that fetal blood sampling was performed
(East 2006; Garite 2000; Kuhnert 2004). However, data were only
available to allow for one of these to be included in a subgroup
analysis (East 2006). None of the remaining subgroup analyses
were conducted, as we were unable to identify trials that addressed
these questions.
We planned to use the following primary outcomes in subgroup
analysis.
1 Caesarean section
2 Hypoxic-ischaemic encephalopathy
3 Neonatal seizures
4 Long-term neurodevelopmental outcome
For fixed-effect inverse variance meta-analyses we planned to as-
sess differences between subgroups by interaction tests (we did
not meta-analyse the subgroups). For random-effects and fixed-
effect meta-analyses using methods other than inverse variance,
we assessed differences between subgroups by inspection of the
subgroups’ confidence intervals; non-overlapping confidence in-
tervals indicated a statistically significant difference in treatment
effect between the subgroups.
The differences in entry criteria for the reported studies made
combined statistical analysis problematic. We addressed this by
considering the following analyses:
(A) nonreassuring fetal heart rate prior to study entry:
(i) gestation from 34 weeks (or from 36 weeks where this was the
earliest gestation enrolled), fetal blood sampling not required prior
to study entry;
(ii) gestation from 36 weeks, fetal blood sampling prior to study
entry;
(iii) gestation from 28 weeks, fetal blood sampling not required
prior to study entry; and
(B) gestation from 36 weeks, nonreassuring fetal status not re-
quired prior to study entry.
One study (Bloom 2006) enrolled women regardless of nonreas-
suring fetal status prior to study entry, i.e. “(A)” above. We in-
cluded the results for all women in relevant analyses, and for the
group of women within the study where nonreassuring fetal status
was reported prior to study entry (i.e. “(B)” above). Therefore in
several analyses (Analysis 1.1, Analysis 1.3, Analysis 2.5, Analysis
2.6), the same data were reported differently, meaning that it was
not appropriate to provide an overall total estimate of effect.
Sensitivity analysis
Inclusion of the study results from Garite 2000 contributed to
heterogeneity for some outcomes (for e.g. Caesarean section over-
all, Analysis 1.1. and Caesarean section for dystocia,Analysis 2.6).
We considered that the overall summary remained useful and used
random-effects to produce it.
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R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
See Characteristics of included studies table.
The search identified six published randomised controlled trials
(Bloom 2006; Caliskan 2009; East 2006; Garite 2000; Klauser
2005;Kuhnert 2004 ), one study published as a conference abstract
only (see Studies awaiting classification, Prieto 2008) and two
observational studies (Andres 2004; Golaszewski 1993). The trial
by Garite 2000 had also been published in a number of forms
and sub analyses addressing issues that were not considered in this
review. Similarly, the trials by East 2006 and Bloom 2006 had
several related publications, some of which were considered in this
review and were added with this update.
Trials with nonreassuring fetal status required prior
to study entry
The trial published by Garite 2000 was conducted in the United
States of America (USA) and compared caesarean section rates
for nonreassuring fetal status when conventional fetal monitoring
(CTG) was used, versus when fetal pulse oximetry was used in ad-
dition to CTG, with reported data on 1010 cases. An unpublished
report included some pilot data for a total of 1189 cases.
Kuhnert 2004 reported a trial from Germany which compared
operative delivery and fetal scalp blood sampling for nonreassuring
fetal status in two groups: those with CTG monitoring and those
with fetal pulse oximetry added to theCTG, for a total of 146 cases.
Fetal blood sampling was required prior to study entry.Whilst not
stated in the report, it is appropriate to consider that if the scalp
pH was nonreassuring, intervention would have been undertaken
to correct this or to deliver the baby prior to enrolment in the
study. It can therefore be considered that this represents, at least
in part, a different study population to that of the other studies.
A single-centre trial from the USA, reported by Klauser 2005, in-
cluded 327 women with gestation from 28 weeks onward. This
study compared caesarean delivery for nonreassuring fetal status
in women with and without fetal pulse oximetry added to CTG
monitoring (Klauser 2005). Interpretation of fetal heart rate mon-
itoring is different in premature babies, compared with term ba-
bies. The report did not allow the reader to distinguish outcomes
by gestational age. It may therefore be appropriate to consider
that this represents a heterogenous population. This would make
subsequent combination with other trials inappropriate. We were
unable to contact the authors to consider analysis by gestation.
An Australian multicentre trial compared operative delivery for
nonreassuring fetal status in those with and without fetal pulse
oximetry added to CTGmonitoring (East 2006) on 600 pregnan-
cies.
The trial reported by Bloom 2006 included 2168 women with a
nonreassuringCTGat the time of study entry, of the 5341 enrolled
in the study overall (see below).
Caliskan 2009 reported a single-centre trial from Turkey, which
enrolled 230 women undergoing induction of labour with miso-
prostol. Women were randomised to either CTG monitoring, or
CTG plus intermittent fetal pulse oximetry.
A conference abstract by Prieto 2008 reported limited findings
from a pilot randomised study comparing the use of fetal pulse
oximetry with fetal electrocardiography, in the presence of a non-
reassuring fetal heart rate trace during labour. We have been un-
able to identify a full report of this study or to contact the study
authors. Given that the likelihood of results being different in a
conference abstract and the final study report, we have elected to
await full publication rather than include the limited results in this
review. This study therefore remains as a study awaiting classifica-
tion.
Trials with nonreassuring fetal status not required
prior to study entry
Bloom 2006 reported a multicentre trial conducted in the USA
(n = 5341), which enrolled nulliparous women with CTG moni-
toring in labour. All participants had a fetal pulse oximetry sensor
placed and were then randomly allocated to the ’open’ arm with
fetal pulse oximetry values displayed or the ’masked’ arm with fetal
pulse oximetry values stored to computer disk and not displayed
to the woman or clinician. These results were analysed separately
from the other studies, as the study population, labouring women
with a CTG, could not be considered in the same manner as those
with a nonreassuring CTG. The report included limited outcomes
for a separate analysis of those with a nonreassuring CTG prior to
study entry.
The study reported by Caliskan 2009 enrolled women from 34
weeks gestation undergoing induction of labour by oral misopros-
tol. All participants had misoprostol administered and were then
randomised to either intermittent fetal pulse oximetry+electronic
fetal monitoring, or electronic fetal monitoring only.
We found no unpublished studies.
Risk of bias in included studies
The published studies were unblinded (in terms of group alloca-
tion) randomised controlled trials, with complete follow up. The
’masked’ group in the study by Bloom 2006meant that the labour-
ing woman and clinicians were blinded to fetal oximetry values.
Outcome assessment of all trials was unblinded with the excep-
tion of (i) a post hoc analysis of partograms in the trial by Garite
2000, constructed to demonstrate progress in labour for all cases
of dystocia (defined) and failed induction of labour (defined), for
which the review author was blinded to group allocation; and (ii)
review of women’s records in the study reported by Bloom 2006,
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when the initial data indicated the presence of a placental abrup-
tion, prolonged fetal heart rate deceleration at the time of sensor
insertion and serious neonatal outcomes, including death or five-
minute Apgar score less than four.
Women in labour at greater than or equal to 28 (Klauser 2005),
34 (Caliskan 2009), or 36 weeks’ gestation (East 2006; Garite
2000; Klauser 2005) who gave informed consent and whose fe-
tuses displayed nonreassuring heart rate traces, were randomised
to conventional cardiotocography monitoring, or to the addition
of fetal pulse oximetry. Management of fetal heart rate patterns
and fetal pulse oximetry followed an algorithm. In contrast to the
other reported trials, the study by Bloom 2006 did not require
nonreassuring fetal status prior to study entry. The ’masked’ group
of this trial is treated in this review as ’cardiotocography-only’ for
the purposes of meta-analysis, since the fetal pulse oximetry val-
ues did not influence clinical decisions. The primary outcome for
each trial was caesarean section or overall operative birth for non-
reassuring fetal status. See ’Characteristics of included studies’ for
further details. Methods of randomisation and allocation conceal-
ment were not reported in some studies (Klauser 2005; Kuhnert
2004). The reports of the trials by Kuhnert 2004 and by Klauser
2005 were less detailed overall than for the other trials. All tri-
als were included in the meta-analysis to allow a comprehensive
representation of the findings. The use of a summary measure of
effect for all trials was not used, however, as the appropriateness of
combining studies with differing quality, entry criteria and signif-
icant heterogeneity if separate analyses were not used, remained
uncertain.
Effects of interventions
We included six trials involving 7724 participants in this review.
(One report from an updated search in October 2009 remains in
Studies awaiting classification, as it is only available in abstract
form and with limited details.)
Primary outcomes
Meta-analysis of five of the six trials resulted in no significant dif-
ferences in the overall caesarean section rate between those moni-
tored with fetal oximetry and those not monitored with fetal pulse
oximetry or for whom the fetal pulse oximetry results were masked
(risk ratio (RR) 0.99, 95% confidence intervals (CI) 0.86 to 1.13).
A smaller study for which fetal blood sampling was required prior
to study entry (n = 146) reported a significant decrease in cae-
sarean section in the fetal oximetry group, compared with the con-
trol group (Kuhnert 2004). Neonatal seizures were rare, with only
one case in the control group of the trial by Garite 2000 and one
clinical case in the intervention group of the trial by East 2006.
Hypoxic ischaemic encephalopathy was reported in only one case,
in the masked group of the study by Bloom 2006. No studies re-
ported details of assessment of long-term disability.
Secondary outcomes: maternal
There was a statistically significant decrease in caesarean section
for nonreassuring fetal status in the fetal pulse oximetry plus CTG
group compared to the CTG group in two of the four analyses:
(i) gestation from 34weeks with fetal blood sampling not required
prior to study entry (RR0.65, 95%CI 0.46 to 0.90); and (ii) when
fetal blood sampling was required prior to study entry (RR 0.03,
95%CI 0.00 to 0.44). There was a statistically significant decrease
in operative delivery (caesarean section, forceps or vacuum birth)
for nonreassuring fetal status when fetal pulse oximetry was added
toCTGmonitoring, in all three studies that reported this outcome
(n = 1756).
There was no statistically significant difference in caesarean sec-
tion for dystocia when fetal pulse oximetry (fetal pulse oximetry)
was added to CTG monitoring, compared with CTG monitoring
alone.
The addition of fetal pulse oximetry to CTG monitoring resulted
innodifferences for overall operative delivery rates (with the excep-
tion of the smaller study reported byKuhnert 2004), endometritis,
intrapartum haemorrhage, postpartum haemorrhage, chorioam-
nionitis, endometritis, uterine rupture, length of hospital stay,
satisfaction with labour or satisfaction with fetal monitoring in
labour, compared toCTG only.Nomaternal deaths occurred. The
study by Kuhnert 2004 reported less antibiotic use in the fetal
pulse oximetry group, compared with the CTG group.
Women reported similar levels of satisfaction with their labour
and fetal monitoring when fetal pulse oximetry was added to CTG
monitoring, compared to CTG monitoring alone (East 2006).
Secondary outcomes: fetal/neonatal
No statistically significant differences were noted for Apgar scores
less than four at five minutes or less than seven at five minutes,
umbilical arterial pH less than 7.10, umbilical arterial base excess
less than -12, admission to the neonatal intensive care unit, length
of hospital stay, death or skin trauma. Transient skin markings
attributable to the fetal oximetry sensor were noted in 11 of 638
babies (2%) Garite 2000; in 30 of 305 babies (10%) East 2006;
and for 152 of 2629 babies (6%) in the open group and 155 of
2712 babies (6%) in the masked group Bloom 2006.
Subgroup analyses
Datawere available fromone trial (East 2006) to allow the planned
subgroup analyses of fetal scalp blood sampling post randomisa-
tion. There were no significant differences in the primary outcome
of caesarean section and no seizures were reported for any of the
babies in this subgroup. Data were not available to allow the re-
maining subgroup analyses to be conducted.
D I S C U S S I O N
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When systematically reviewed, five of the six published trials (with
some unpublished data available), comparing fetal intrapartum
pulse oximetry with CTG ormasked fetal pulse oximetry, reported
no difference in the overall caesarean section rate between the fetal
pulse oximetry group and the CTG group. One smaller study did
note a significant difference in favour of the fetal pulse oximetry
plus CTG group.
Meta-analysis of the four studies with nonreassuring fetal status
from 34 weeks’ gestation prior to randomisation demonstrated a
reduction in caesarean section for nonreassuring fetal status, with
no differences in neonatal outcomes. That is, a decision not to
perform a caesarean section for nonreassuring fetal status in the
fetal pulse oximetry group did not result in worse outcomes for
those babies (but a larger sample would be required to demon-
strate a difference in such low-prevalence outcomes). There were
no between-group differences in caesarean section for nonreas-
suring fetal status when all participants in the largest study were
considered, when analysed without consideration of fetal status at
study entry.
These findings from more than 7000 participants in high-quality
studies provide substantial evidence to suggest that knowledge of
fetal pulse oximetry values does not influence overall caesarean sec-
tion rate. However, several issues warrant consideration: (1) does
the indication for caesarean section matter if the overall incidence
of caesarean section is the same? (2) Does the presence of a fetal
oximetry sensor contribute to dystocia?
The decision pathway leading to performing a caesarean section
may be important. The additional information that fetal pulse
oximetry can provide, when a nonreassuring fetal heart rate trace
has been identified, may translate to avoidance of a caesarean sec-
tion for nonreassuring fetal status, with its associated stress lev-
els for the mother and resource implications for the health ser-
vice providers. An ’inevitable’ caesarean section may still be per-
formed for other indications, when the woman has had more time
to consider her options. Staffing levels can also be adjusted over a
number of hours, rather than the immediate and potentially costly
provision of staff for an emergency operation. One trial reported
that the addition of fetal pulse oximetry to CTG monitoring was
cost effective in reducing operative delivery for nonreassuring fetal
status (East 2006).
When the findings of the first trials of fetal pulse oximetry became
available, there was debate about why the incidence of caesarean
section for dystocia more than doubled from 9% in the CTG-only
group to 19% when fetal pulse oximetry was added. The investi-
gators explored several possible causes for the increase in dystocia
in the fetal pulse oximetry group, including potential mislabelling
of dystocia and the presence of the oximetry sensor slowing the
labour (Garite 2000). The authors concluded that mislabelling
of the indication for caesarean section had not occurred and the
presence of the sensor did not result in a longer labour. They sug-
gested that the nonreassuring CTG may indicate an underlying
risk for dystocia (Garite 2000). To test this hypothesis, Porreco
2004 conducted a multicentre, prospective, observational cohort
study of fetal pulse oximetry innulliparous labouringwomen, with
a standardised labour management protocol and a specific focus
on the management of dystocia (defined). The investigators con-
cluded that the presence of persistent, progressive andmoderate to
severely nonreassuring CTGs may predict the need for delivery by
caesarean section for dystocia, despite adequate fetal oxygenation
(Porreco 2004). No other trials in this systematic review demon-
strated a difference in caesarean section for dystocia. However, the
incidence of dystocia in each trial varied: from 11% in the fe-
tal pulse oximetry group and 14% in the CTG-only group (East
2006) to 19% for all women in both the open and masked groups,
where all participants had a fetal oximetry sensor placed (Bloom
2006), which was similar to that of the fetal pulse oximetry group
of the Garite 2000.The incidence of dystocia was much lower in
the study reported by Caliskan 2009 (2.6% in the fetal oximetry
group and 3.4% in the CTG-only group). These researchers con-
sidered that the intermittent use of the fetal oximetry probe may
have avoided an over representation of dystocia in the oximetry
group. It remains possible that the presence of a fetal oximetry
sensor alongside the fetal head contributes to dystocia.
Women’s reports of satisfaction with their labour and with fetal
monitoring were similar when fetal pulse oximetry was added to
CTG monitoring, compared to CTG monitoring alone. This is
an important consideration, given that the use of technology may
impact on women’s perceived control over their labour experience
(Wagner 2001). Although an ideal study would compare women’s
satisfaction with fetal pulse oximetry and without any technology,
such a study is not feasible. It can be considered, however, that
once continuous CTG monitoring is in use during labour, the
addition of fetal pulse oximetry technology does not adversely
affect women’s perceptions of their labour experience or of fetal
monitoring overall.
Both the clinicians and the women in labour were unblinded to
the use of a fetal oximeter and display of fetal oximetry values in
the intervention groups of the trials (Bloom 2006; Caliskan 2009;
East 2006; Garite 2000; Klauser 2005; Kuhnert 2004). Is blind-
ing feasible? Given that clinicians were to act on the results of the
intervention, that is, the fetal pulse oximetry readings, it would
not be possible to blind at that stage. Bloom 2006 placed a fetal
oximetry sensor with values stored to computer, thus blinding the
fetal pulse oximetry values to the labouring woman and her clini-
cians. A design feature of future studies could be blinded outcome
assessment: that is, present the data in two groups, not revealing
actual group allocation.
Safety of fetal pulse oximetry has been partially addressed by the
published trials: fetal/neonatal and maternal outcomes were not
different in the two groups of monitoring, although power was
low for some low prevalence outcomes. Long-term neurodevelop-
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mental outcome has not been measured.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Is fetal pulse oximetry ready for use in clinical practice? Euro-
pean clinicians published guidelines for fetal pulse oximetry use
(Kuhnert 1998; Saling 1996) that were consistent with the man-
agement of fetal pulse oximetry in Garite 2000 and prior to its
results being known. Only one small randomised controlled trial
of fetal pulse oximetry has since been reported from Europe to test
these guidelines (Kuhnert 2004). That trial did report a significant
decrease in both overall caesarean section rate and caesarean sec-
tion for nonreassuring fetal status when fetal pulse oximetry was
added to cardiotocography (CTG) monitoring, compared with
CTG only (Kuhnert 2004). Current data suggest that knowledge
of fetal pulse oximetry does not affect overall caesarean section
rates.
The American College of Obstetrics and Gynecology (ACOG) re-
viewed the results of the trial reported by Garite 2000 and recom-
mended further trials before the introduction of fetal pulse oxime-
try into clinical practice (ACOG 2001). Their recommendation
was based mainly on the increase in dystocia reported with the use
of fetal pulse oximetry and the potential to increase fetal moni-
toring costs without improving clinical outcomes (ACOG 2001).
One trial reported that the addition of fetal pulse oximetry to car-
diotocography was cost effective in reducing operative delivery for
nonreassuring fetal status (East 2006).
The use of CTG has some parallels. Current clinical practice rec-
ommendations are that the clinician and the individual woman
should consider the appropriateness ofCTGto enable an informed
choice for each case (Alfirevic 2006; RCOG 2001). Given the high
quality of evidence from several of the reported fetal pulse oxime-
try trials and the reduction in caesarean section for nonreassuring
fetal status (but not for overall caesarean section rates) in those for
which a nonreassuring CTG was required prior to study entry, it
may be prudent when developing recommendations to encourage
the individual woman and her clinicians to make the decision to
use or not use fetal pulse oximetry. Unlike CTG, however, the ran-
domised controlled trials of fetal pulse oximetry have been con-
ducted prior to widespread clinical acceptance and medico-legal
expectation of fetal pulse oximetry usage where there is concern
about fetal well-being.
Commercial availability of the fetal pulse oximetry system used
in the studies was discontinued during 2006. Other systems that
have not yet been subject to trials remain available commercially.
The data provide limited support for the use of fetal pulse oximetry
when used in the presence of a nonreassuring CTG, to reduce
caesarean section for nonreassuring fetal status. This finding is
similar to other tests available to evaluate fetal well-being in labour
(fetal scalp blood sampling for pH estimation (Alfirevic 2006) and
fetal electrocardiogram (Neilson 2006)), which also do not reduce
caesarean sections. A better method to evaluate fetal well-being in
labour is required.
Implications for research
Further trials could address: entry criteria related to the severity of
nonreassuring CTG patterns; action levels for fetal pulse oximetry
values, such as a decline by 10% or 20%, rather than an absolute
cut-off value; and the endpoint of long-term neurodevelopmental
outcomes. The ideal study to address the issue of dystocia when a
fetal pulse oximetry sensor is placed alongside the fetal head would
compare caesarean section for dystocia in three groups: those with
fetal oximetry displayed, those with fetal pulse oximetry masked
and those without fetal pulse oximetry. Further studies using fetal
oximetry sensors attached to the fetal scalp, rather than placed
alongside the fetal head, could also be considered.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bloom 2006
Methods RCT.
Participants Nulliparous women from 36 weeks’ gestation with a singleton pregnancy and cephalic
presentation, in early labour (2-5 cm cervical dilatation) with ruptured amniotic mem-
branes who gave informed consent
Interventions ’Open’ group: FPO sensor placed and FPO values displayed.
’Masked’ group: FPO sensor placed and FPO values not displayed (FPO values recorded
on computer)
Both groups: standard fetal heart rate monitoring; labour management at the clinician’s
discretion
Outcomes Primary: caesarean section (any indication).
Secondary: caesarean section for nonreassuring fetal status or dystocia; “fetal vulnerability
index” (stillbirth, neonatal death, 5-min Apgar score less than 3, umbilical pH less than
or equal to 7, seizures, admission to neonatal intensive care unit for greater than or equal
to 24 hours); other neonatal morbidity
Notes Fetal oximetry system used: Nellcor OxiFirst.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk Unclear.
Blinding?
All outcomes
High risk Blinding of intervention = women and clinicians blinded to
FPO values in the ’masked’ group: however, not actually blinded
to intervention (C); completeness of follow up = A; blinding
of outcome assessment = B, however, if certain outcomes were
identified, blinded chart review authors then confirmed the out-
comes
Incomplete outcome data addressed?
All outcomes
Low risk No evidence of incomplete outcome data.
Free of selective reporting? Low risk No evidence of selective reporting. Report aligns with limited
details of protocol published when RCT in progress
Free of other bias? Low risk No evidence of other bias.
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Caliskan 2009
Methods RCT, single centre (Turkey).
Participants Women from 34 weeks’ gestation undergoing induction of labour with oral misoprostol
Inclusion: singleton live pregnancy with vertex presentation and maternal and/or fetal
indications for induction of labour; gestational age from 34 weeks; Bishop score less than
or equal to 5; absence of spontaneous uterine contractions; estimated fetal body weight
less than 4250 g; reactive non-stress test
Exclusion: fetal demise; gestational age less than 34 weeks; known hypersensitivity to
prostaglandin; previous caesarean section or other uterine surgery; contraindication to
vaginal delivery
Interventions Group 1: electronic fetal monitoring by CTG only. If the CTG was reassuring, labour
continued unless otherwise indicated. If the CTG was nonreassuring (defined), simple
measures, including lateral positioning, were instigated, with escalation to operative
delivery if simple measures were not effective
Group 2: CTG plus FSpO2 monitoring - intermittently for 15 minutes every 2 hours. If
reassuring it was removed. If nonreassuring, remained in situ. If the CTG was reassuring
and FSpO2 values were greater than or equal to 30%, labour continued unless otherwise
indicated. If the CTGwas nonreassuring (defined) and FSpO2 values were less than 30%
for 3 minutes, simple measures, including lateral positioning, were instigated. If FSpO2
values remained < 30% for 10 minutes, then operative delivery was performed
Outcomes Primary outcome: caesarean delivery rates.
Secondary outcomes: induction to delivery interval, caesarean section for nonreassuring
CTG, neonatal outcomes, including umbilical arterial pH < 7.16, admission to neonatal
intensive care
Notes Fetal oximetry system used: Nellcor OxiFirst.
37 weeks used as ’restriction point’ to randomly allocate preterm and term fetuses to
the 2 groups. This is interpreted as stratification by term/preterm, however, no further
details provided of outcomes within these groups
Datawere not available to allow subgroup analysis in this review by term/preterm. Similar
numbers of term (total n = 195)/preterm (total n = 35) were randomised to the control
and intervention groups, with the larger proportion being term in each group. There were
similar neonatal outcomes (including birthweight and admission to neonatal intensive
care unit), both between the groups and compared with other studies enrolling over 36
weeks. We have therefore included these participants in the analyses of later gestations,
renaming the analyses that include participants from this study as “... gestation from 34
weeks ...”
Attempts at establishing contact details to clarify this were unsuccessful
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Reported to be “Directed by a physician”.
Allocation concealment? Low risk Sequentially numbered opaque envelopes.
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Caliskan 2009 (Continued)
Blinding?
All outcomes
High risk It would not have been feasible to blind the clinician or
participant, given that FSpO2 values were used for clin-
ical judgement. It is not stated whether or not outcome
assessment was blinded
Incomplete outcome data addressed?
All outcomes
Low risk No evidence of incomplete outcome data.
Free of selective reporting? Low risk No evidence of selective reporting, however, protocol not
published
Free of other bias? Low risk No evidence of other bias.
East 2006
Methods Multicentre RCT.
Survey of women’s perceptions: identical surveys to participants in each group within a
few days of giving birth and 3 months later. Women were asked to rate their experience
in 3 domains: labour (maximum score 12), fetal monitoring (maximum score 16) and
participation in research (maximum score 12).
Cost-effectiveness analysis the RCT. Costs included diagnosis-related group costs, FBS,
medications, use of oxygen or intravenous fluid, or both, FPO. Effect was the primary
outcome of the RCT (operative delivery for nonreassuring fetal status)
Participants 601 women in labour. 1 exclusion, leaving 600 analysed.
Inclusion criteria: nonreassuring CTG (defined),
>
= 36 weeks’ gestation, early or active
labour, ruptured amniotic membranes or eligible for artificial rupture of membranes
Exclusion criteria: multiple gestations, non vertex presentation, placenta praevia, abrup-
tio placentae, uterine anomaly, antepartum haemorrhage, fetal anomaly, known signifi-
cant viral infections (e.g. HIV), any other contraindications to invasive monitoring such
as thrombocytopenia
Interventions Control group: fetal heart rate monitoring (CTG) (doppler/fetal scalp electrode)
Intervention group: CTG plus fetal pulse oximetry. Protocol for action with reassuring (
>
=
30%) and nonreassuring fetal oximetry values (< 30% for 10 minutes, or not recording)
Outcomes Primary outcome: operative delivery (caesarean section, vacuum, forceps) for nonreas-
suring fetal status
Maternal outcomes including: caesarean section and assisted vaginal delivery for nonre-
assuring fetal status; caesarean and assisted vaginal delivery section for dystocia/failure
to progress; caesarean or assisted vaginal birth for combined indication of nonreassuring
fetal status and dystocia; caesarean section; assisted vaginal birth; spontaneous vaginal
birth; labour interventions and fetal evaluations (e.g. scalp pH); endometritis; postpar-
tum haemorrhage; length of stay
Women’s perceptions: satisfaction measured in 3 domains: labour, fetal monitoring and
participation in research
Neonatal outcomes including: Apgar scores; umbilical cord blood gases; resuscitation;
admission to neonatal intensive care unit; length of hospital stay
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East 2006 (Continued)
Economic analysis: cost-effectiveness of FPO to prevent operative delivery for nonreas-
suring fetal status
Notes Sample size calculation: yes, based on reduction in caesarean section rate for nonreassur-
ing fetal status.
Fetal oximetry system used: Nellcor OxiFirst.
Women’s perceptions: results from the first survey are used in this report
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Developed by research associate not in-
volved in recruitment.
Allocation concealment? Low risk Adequate, through use of password pro-
tected computer randomisation system
Blinding?
All outcomes
High risk Not feasible to blind participants or clini-
cians. Outcome analysis unblinded except
for interim analysis where data presented to
data monitoring committee in 2 unlabelled
groups by study associate
Incomplete outcome data addressed?
All outcomes
Low risk All participants accounted for.
Free of selective reporting? Low risk No evidence of selective reporting.
Free of other bias? High risk Authors declared commercial funding in all
publications.
Garite 2000
Methods Random allocation: telephone randomisation.
Participants 1189 women in labour. This consisted of 1010 in the published trial and 179 in a pilot
of the trial conducted using the same protocol, where unpublished data were accessible
Inclusion criteria: nonreassuring CTG,
>
= 36 weeks’ gestation, active labour, single fetus,
cephalic presentation, cervical dilatation of at least 2 cm and at station -2 or below,
ruptured amniotic membranes (or have amniotomy)
Exclusion criteria: planned caesarean section, placenta praevia, need for immediate de-
livery, active genital herpes or known HIV infection, participation in other studies
Interventions Control group: fetal heart rate monitoring (CTG) (doppler/fetal scalp electrode)
Study group: CTG plus fetal pulse oximetry. Protocol for action with reassuring and
nonreassuring fetal oximetry values
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Garite 2000 (Continued)
Outcomes Caesarean section for nonreassuring status; caesarean section for all indications; caesarean
section for fetal intolerance to labour with dystocia, mixed indication; caesarean dystocia,
single indication; spontaneous vaginal delivery; assisted vaginal delivery for nonreassuring
fetal status or for all other indications; fetal heart rate patterns; labour interventions and
fetal evaluations (e.g. scalp pH)
Neonatal outcomes including: Apgar scores; umbilical cord blood gases; resuscitation;
admission to neonatal intensive care unit; length of hospital stay
Maternal outcomes including: endometritis; length of stay; bleeding; uterine rupture;
intrapartum fever
Notes Some additional unpublished data from a pilot of the trial, using the same protocol, were
available.
Further data were requested but were unable to be accessed.
Sample size calculation: yes, based on reduction in caesarean section rate for nonreassur-
ing fetal status.
Fetal oximetry system used: Nellcor OxiFirst.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Computer randomisation.
Allocation concealment? Low risk Adequate, with computer randomisation.
Blinding?
All outcomes
High risk Participants, clinicians and researchers un-
blinded. Some blinded outcome analysis, e.
g. retrospective examination of partograms
to determine diagnosis of dystocia
Incomplete outcome data addressed?
All outcomes
High risk All participant data accounted for.
Free of selective reporting? Low risk No evidence of selective reporting. Avail-
able data for this review included a report to
the Food and Drug Administration, which
included comprehensive and otherwise un-
published results that were consistent with
published findings
Free of other bias? High risk Commercially funded study, acknowl-
edged by report authors.
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Klauser 2005
Methods Single-centre RCT.
Participants 360 women in labour. Control group: 1 post randomisation exclusion as no consent.
Intervention group: 30 post randomisation exclusions where FPO sensor not placed and
2 additional exclusions due to randomisation issues
Inclusion criteria: nonreassuring CTG,
>
= 28 weeks’ gestation, single fetus, cephalic pre-
sentation, cervical dilatation of at least 2 cm and at station -5 or below, ruptured amniotic
membranes (spontaneous or artificial)
Exclusion criteria: planned caesarean section, contraindication to vaginal delivery (in-
cluding genital herpes, transverse lie), unexplained vaginal bleeding, placenta praevia,
ominous CTG requiring immediate delivery, known HIV infection, hepatitis B or C,
unable to give consent due to intrapartum parenteral analgesia
Interventions Control group: fetal heart rate monitoring (CTG) (Doppler/fetal scalp electrode)
Study group: CTG plus fetal pulse oximetry (Nellcor OxiFirst). Protocol for action with
reassuring fetal oximetry (
>
= 30%) and nonreassuring values (< 30% for 3 minutes)
Outcomes Primary outcome: caesarean section for nonreassuring fetal status
Maternal outcomes: caesarean section for all indications; caesarean section for dystocia;
amnioinfusion and length of labour
Neonatal outcomes including: Apgar scores; umbilical cord blood gases; resuscitation;
admission to neonatal intensive care unit
Notes Further data were requested, awaiting reply.
Sample size calculation: yes, based on reduction in caesarean section rate for nonreassur-
ing fetal status.
Fetal oximetry system used: Nellcor OxiFirst.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Method of randomisation not stated.
Allocation concealment? Unclear risk Unclear. No mention in the report, although two participants
were excluded on the basis of “randomization issues”
Blinding?
All outcomes
High risk The report did not comment on blinding, but it is implicit that
the clinician and participant were unblinded, given that FSpO2
values were used for clinical judgement
Incomplete outcome data addressed?
All outcomes
Low risk Accounted for in diagram.
Free of selective reporting? Low risk No evidence of selective reporting.
Free of other bias? Low risk No evidence of other bias.
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Kuhnert 2004
Methods Single-centre, RCT.
Participants 146 women in labour.
Inclusion criteria: CTG with International Federation of Gynecology and Obstetrics
(FIGO) score
<
= 8, gestational age
>
= 36 weeks, active labour, single fetus, cephalic presen-
tation, cervical dilatation of at least 2 cm and at station -2 or below, ruptured amniotic
membranes (or have amniotomy). All cases had FBS prior to randomisation
Exclusion criteria: planned caesarean section, placenta praevia, need for immediate de-
livery, active genital herpes or known HIV infection
Interventions Control group: fetal heart rate monitoring (CTG) and FBS. Protocol for action with
reassuring, suspicious and pathologic CTG and FBS pH values
Intervention group: CTG plus FBS plus FPO. Protocol for action with reassuring (
>
=
30%) and nonreassuring FPO values (< 30% for
>
= 10 mins or repeatedly (’summation
effect’), and for reassuring and nonreassuring CTG and FBS pH
Outcomes Caesarean section or vacuum extraction for pathologic CTG; caesarean section or vac-
uum extraction for all indications; caesarean section or vacuum for arrest of labour; cae-
sarean section for pelvic malformation or amnioinfection; vacuum extraction for mater-
nal exhaustion; spontaneous vaginal delivery; fetal heart rate patterns; FBS (including
pH)
Neonatal outcomes including: umbilical cord blood gases; resuscitation; admission to
neonatal intensive care unit
Maternal outcomes: ’adverse maternal events’.
Notes Some additional unpublished data were provided by the authors (use of antibiotics,
haemorrhage, chorioamnionitis, endometritis, uterine rupture, length of hospital stay,
satisfaction with labour and fetal monitoring, death, neonatal skin trauma, Apgar score,
umbilical arterial base excess, admission to neonatal intensive care, hypoxic-ischaemic
encephalopathy, seizures, long-term disability). No details of the assessment of long-term
disability were provided (e.g. age of the infant, assessments made)
Sample size calculation: no.
Fetal oximetry system used: Nellcor OxiFirst.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Random allocation: method not stated and not provided on
request
Allocation concealment? Unclear risk Unclear. No details provided in the report.
Blinding?
All outcomes
Unclear risk It would not have been feasible to blind the clinician or partici-
pant, given that FSpO2 values were used for clinical judgement.
The report states “data acquisition was done anonymously for
both group”. It is unclear whether this related to de-identifying
the data (likely) or that the data were collected without knowl-
edge of group allocation
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Kuhnert 2004 (Continued)
Incomplete outcome data addressed?
All outcomes
Unclear risk No supporting evidence of inclusion of all participants.
Free of selective reporting? Unclear risk Results differ widely from other published studies. It is unclear
whether there was any selective reporting
Free of other bias? Unclear risk The limited details in the report (see above) make it difficult to
exclude the possibility of other bias
CTG: cardiotocography
FBS: fetal blood sampling (scalp)
FPO: fetal pulse oximetry
FSpO2: fetal oxygen saturation value
HIV: human immunodeficiency virus
min: minute
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andres 2004 This study was conducted in Spain. It compared caesarean section rates for pathological or nonreassuring CTG
when FPO was added to CTG monitoring or when FPO was not used. The groups were not randomised
Golaszewski 1993 This was an observational study of fetal pulse oximetry, where participants were randomised to be monitored
with 1 of 2 oximeters
CTG: cardiotocography
FPO: fetal pulse oximetry
Characteristics of studies awaiting assessment [ordered by study ID]
Prieto 2008
Methods Randomised pilot study, comparing use of fetal ECG and fetal pulse oximetry
Participants Singleton pregnancy with nonreassuring fetal status in active stage of labour
Conference abstract does not give numbers of participants.
Interventions Fetal ECG group: STAN21 system in use.
Fetal pulse oximetry: intermittent recordings of FPO if values reassuring, continuous FPO recording if values non-
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Prieto 2008 (Continued)
reassuring
Outcomes Caesarean section (overall and for indications of nonreassuring fetal status / dystocia); Umbilical blood pH; Apgar
scores
Notes Conference abstract only. No publication available on PubMed search of 25 May 2010 and no author contact details
identified
ECG: electrocardiogram
FPO: fetal pulse oximetry
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D A T A A N D A N A L Y S E S
Comparison 1. Primary outcomes: FPO + CTG versus CTG only
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Caesarean section 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Gestation from 34 weeks,
FBS not required prior to study
entry
4 4008 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.86, 1.13]
1.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.24, 0.81]
1.3 Gestation from 28 weeks,
FBS not required prior to study
entry
1 327 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.76, 1.14]
1.4 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.87, 1.04]
2 Hypoxic-ischaemic
encephalopathy
3 6087 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.44]
2.1 Gestation from 36 weeks,
FBS not required prior to study
entry
1 600 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.44]
3 Neonatal seizures 4 7276 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.21, 2.32]
3.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1789 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.10, 8.79]
3.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.15, 2.59]
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Comparison 2. Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
5 Caesarean section for
nonreassuring fetal status
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Gestation from 34 weeks,
FBS not required prior to study
entry
4 4008 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.46, 0.90]
5.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.03 [0.00, 0.44]
5.3 Gestation from 28 weeks,
FBS not required prior to study
entry
1 327 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.64, 1.24]
5.4 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.09]
6 Caesarean section for dystocia 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Gestation from 34 weeks,
FBS not required prior to study
entry
4 4008 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.91, 2.09]
6.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 1.4 [0.47, 4.21]
6.3 Gestation from 28 weeks,
FBS not required prior to study
entry
1 327 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.66, 1.46]
6.4 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.87, 1.08]
7 Operative delivery (caesarean
section, forceps, vacuum
extraction) for all indications
5 7327 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.81, 1.06]
7.1 Gestation from 34 weeks,
FBS not required prior to study
entry
3 1840 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.92, 1.15]
7.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.36, 0.73]
7.3 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.90, 1.03]
8 Operative delivery (caesarean
section, forceps, vacuum) for
nonreassuring fetal status
3 1756 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.27, 0.96]
8.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1610 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.62, 0.89]
8.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.05 [0.01, 0.22]
9 Use of intrapartum antibiotics 2 746 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.38, 1.61]
26Fetal pulse oximetry for fetal assessment in labour (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
9.1 Gestation from 36 weeks,
FBS not required prior to study
entry
1 600 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.87, 1.35]
9.2 Gestation from 36 weeks,
FBS required prior to study
entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.30, 0.88]
10 Overall antibiotic use 1 146 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.30, 0.88]
10.1 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.30, 0.88]
11 Intrapartum haemorrhage 3 1756 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.52, 3.81]
11.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1610 Risk Ratio (M-H, Random, 95% CI) 1.48 [0.51, 4.31]
11.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.06, 15.69]
12 Postpartum haemorrhage 3 1935 Risk Ratio (M-H, Random, 95% CI) 1.52 [0.53, 4.39]
12.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1789 Risk Ratio (M-H, Random, 95% CI) 1.52 [0.53, 4.39]
12.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Chorioamnionitis 2 5487 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.85, 1.16]
13.1 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.11, 3.87]
13.2 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.86, 1.17]
14 Endometritis 4 7276 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.79, 1.26]
14.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1789 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.43, 3.88]
14.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.3 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.76, 1.26]
15 Uterine rupture 3 1935 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.12, 6.13]
15.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1789 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.12, 6.13]
15.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16 Length of hospital stay (days) 2 746 Mean Difference (IV, Random, 95% CI) -0.05 [-0.32, 0.22]
16.1 Gestation from 36 weeks,
FBS not required prior to study
entry
1 600 Mean Difference (IV, Random, 95% CI) -0.06 [-0.36, 0.24]
16.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Mean Difference (IV, Random, 95% CI) 0.0 [-0.65, 0.65]
17 Satisfaction with labour 1 448 Mean Difference (IV, Random, 95% CI) 0.20 [-0.16, 0.56]
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17.1 Gestation from 36 weeks,
FBS not required prior to study
entry
1 448 Mean Difference (IV, Random, 95% CI) 0.20 [-0.16, 0.56]
18 Satisfaction with fetal
monitoring in labour
1 448 Mean Difference (IV, Random, 95% CI) 0.40 [-0.05, 0.85]
18.1 Gestation from 36 weeks,
FBS not required prior to study
entry
1 448 Mean Difference (IV, Random, 95% CI) 0.40 [-0.05, 0.85]
19 Death 3 1935 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1789 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
20 Skin trauma 2 746 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.16, 3.21]
20.1 Gestation from 36 weeks,
FBS not required prior to study
entry
1 600 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.16, 3.21]
20.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21 Apgar score less than 4 at 5
minutes
4 7276 Risk Ratio (M-H, Random, 95% CI) 2.14 [0.60, 7.63]
21.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1789 Risk Ratio (M-H, Random, 95% CI) 2.60 [0.11, 63.70]
21.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21.3 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 2.06 [0.52, 8.24]
22 Apgar score less than 7 at 5
minutes
5 2492 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.41, 1.18]
22.1 Gestation from 34 weeks,
FBS not required prior to study
entry
3 2019 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.38, 1.18]
22.2 Gestation from 36
weeks, FBS required prior to
study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.12, 72.45]
22.3 Gestation from 28 weeks,
FBS not required prior to study
entry
1 327 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.17, 2.91]
23 Umbilical arterial pH less than
7.10
4 2174 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.45, 1.30]
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23.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1701 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.66, 1.53]
23.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.35]
23.3 Gestation from 28 weeks,
FBS not required prior to study
entry
1 327 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.17, 1.24]
24 Umbilical arterial base excess
less than -12
3 1816 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.59, 1.86]
24.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1670 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.57, 1.92]
24.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.14, 6.91]
25 Admission to neonatal intensive
care unit
6 7833 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.83, 1.14]
25.1 Gestation from 34 weeks,
FBS not required prior to study
entry
3 2019 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.85, 1.40]
25.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.30, 3.31]
25.3 Gestation from 28 weeks,
FBS not required prior to study
entry
1 327 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.55, 1.63]
25.4 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.70, 1.11]
26 Length of hospital stay (days) 2 746 Mean Difference (IV, Random, 95% CI) 0.0 [-0.23, 0.23]
26.1 Gestation from 36 weeks,
FBS not required prior to study
entry
1 600 Mean Difference (IV, Random, 95% CI) 0.0 [-0.33, 0.33]
26.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Mean Difference (IV, Random, 95% CI) 0.0 [-0.32, 0.32]
27 Death 4 7276 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.19, 3.13]
27.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1789 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.20, 4.44]
27.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
27.3 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.44]
28 Death, hypoxic-ischaemic
encephalopathy, or both
4 7276 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.17, 2.73]
28.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1789 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.20, 4.44]
28.2 Gestation from 36
weeks, FBS required prior to
study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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28.3 Gestation from 36 weeks,
nonreassuring fetal status not
required prior to study entry
1 5341 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.01, 4.30]
29 Death, seizures, or both 3 1935 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.22, 3.55]
29.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1789 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.22, 3.55]
29.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
30 Death, long-term
neurodevelopmental problem,
or both
3 1935 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.20, 4.44]
30.1 Gestation from 36 weeks,
FBS not required prior to study
entry
2 1789 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.20, 4.44]
30.2 Gestation from 36 weeks,
FBS prior to study entry
1 146 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Subgroup: fetal blood sampling: primary outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Caesarean section 1 198 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.94, 1.60]
2 Neonatal seizures 1 198 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Primary outcomes: FPO + CTG versus CTG only, Outcome 1 Caesarean
section.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 1 Primary outcomes: FPO + CTG versus CTG only
Outcome: 1 Caesarean section
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 34 weeks, FBS not required prior to study entry
Garite 2000 147/508 130/502 25.3 % 1.12 [ 0.91, 1.37 ]
East 2006 140/305 142/295 30.2 % 0.95 [ 0.80, 1.13 ]
Bloom 2006 327/1055 339/1113 38.5 % 1.02 [ 0.90, 1.15 ]
Caliskan 2009 18/114 31/116 6.0 % 0.59 [ 0.35, 0.99 ]
Subtotal (95% CI) 1982 2026 100.0 % 0.99 [ 0.86, 1.13 ]
Total events: 632 (FPO + CTG), 642 (CTG only)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.47, df = 3 (P = 0.14); I2 =45%
Test for overall effect: Z = 0.16 (P = 0.87)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 12/73 27/73 100.0 % 0.44 [ 0.24, 0.81 ]
Subtotal (95% CI) 73 73 100.0 % 0.44 [ 0.24, 0.81 ]
Total events: 12 (FPO + CTG), 27 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0078)
3 Gestation from 28 weeks, FBS not required prior to study entry
Klauser 2005 77/150 98/177 100.0 % 0.93 [ 0.76, 1.14 ]
Subtotal (95% CI) 150 177 100.0 % 0.93 [ 0.76, 1.14 ]
Total events: 77 (FPO + CTG), 98 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
4 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 692/2629 747/2712 100.0 % 0.96 [ 0.87, 1.04 ]
Subtotal (95% CI) 2629 2712 100.0 % 0.96 [ 0.87, 1.04 ]
Total events: 692 (FPO + CTG), 747 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
0.1 0.2 0.5 1 2 5 10
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Analysis 1.2. Comparison 1 Primary outcomes: FPO + CTG versus CTG only, Outcome 2 Hypoxic-
ischaemic encephalopathy.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 1 Primary outcomes: FPO + CTG versus CTG only
Outcome: 2 Hypoxic-ischaemic encephalopathy
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
East 2006 0/305 0/295 Not estimable
Subtotal (95% CI) 305 295 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 0/2629 1/2712 100.0 % 0.34 [ 0.01, 8.44 ]
Subtotal (95% CI) 2629 2712 100.0 % 0.34 [ 0.01, 8.44 ]
Total events: 0 (FPO + CTG), 1 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Total (95% CI) 3007 3080 100.0 % 0.34 [ 0.01, 8.44 ]
Total events: 0 (FPO + CTG), 1 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
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Analysis 1.3. Comparison 1 Primary outcomes: FPO + CTG versus CTG only, Outcome 3 Neonatal seizures.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 1 Primary outcomes: FPO + CTG versus CTG only
Outcome: 3 Neonatal seizures
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 0/637 1/552 14.3 % 0.29 [ 0.01, 7.08 ]
East 2006 1/305 0/295 14.3 % 2.90 [ 0.12, 70.95 ]
Subtotal (95% CI) 942 847 28.6 % 0.92 [ 0.10, 8.79 ]
Total events: 1 (FPO + CTG), 1 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.00, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 3/2629 5/2712 71.4 % 0.62 [ 0.15, 2.59 ]
Subtotal (95% CI) 2629 2712 71.4 % 0.62 [ 0.15, 2.59 ]
Total events: 3 (FPO + CTG), 5 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 3644 3632 100.0 % 0.69 [ 0.21, 2.32 ]
Total events: 4 (FPO + CTG), 6 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.08, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
0.01 0.1 1 10 100
Favours FPO + CTG Favours CTG only
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Analysis 2.5. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 5
Caesarean section for nonreassuring fetal status.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 5 Caesarean section for nonreassuring fetal status
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 34 weeks, FBS not required prior to study entry
Garite 2000 23/508 51/502 22.5 % 0.45 [ 0.28, 0.72 ]
East 2006 42/305 59/295 28.0 % 0.69 [ 0.48, 0.99 ]
Bloom 2006 104/1055 123/1113 33.9 % 0.89 [ 0.70, 1.14 ]
Caliskan 2009 11/114 23/116 15.6 % 0.49 [ 0.25, 0.95 ]
Subtotal (95% CI) 1982 2026 100.0 % 0.65 [ 0.46, 0.90 ]
Total events: 180 (FPO + CTG), 256 (CTG only)
Heterogeneity: Tau2 = 0.07; Chi2 = 8.16, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 2.56 (P = 0.010)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 18/73 100.0 % 0.03 [ 0.00, 0.44 ]
Subtotal (95% CI) 73 73 100.0 % 0.03 [ 0.00, 0.44 ]
Total events: 0 (FPO + CTG), 18 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
3 Gestation from 28 weeks, FBS not required prior to study entry
Klauser 2005 43/150 57/177 100.0 % 0.89 [ 0.64, 1.24 ]
Subtotal (95% CI) 150 177 100.0 % 0.89 [ 0.64, 1.24 ]
Total events: 43 (FPO + CTG), 57 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
4 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 187/2629 213/2712 100.0 % 0.91 [ 0.75, 1.09 ]
Subtotal (95% CI) 2629 2712 100.0 % 0.91 [ 0.75, 1.09 ]
Total events: 187 (FPO + CTG), 213 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
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Analysis 2.6. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 6
Caesarean section for dystocia.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 6 Caesarean section for dystocia
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 34 weeks, FBS not required prior to study entry
Garite 2000 94/508 43/502 30.4 % 2.16 [ 1.54, 3.03 ]
East 2006 44/305 32/295 27.2 % 1.33 [ 0.87, 2.04 ]
Bloom 2006 216/1055 210/1113 35.9 % 1.09 [ 0.92, 1.29 ]
Caliskan 2009 3/114 4/116 6.5 % 0.76 [ 0.17, 3.33 ]
Subtotal (95% CI) 1982 2026 100.0 % 1.38 [ 0.91, 2.09 ]
Total events: 357 (FPO + CTG), 289 (CTG only)
Heterogeneity: Tau2 = 0.12; Chi2 = 13.22, df = 3 (P = 0.004); I2 =77%
Test for overall effect: Z = 1.53 (P = 0.13)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 7/73 5/73 100.0 % 1.40 [ 0.47, 4.21 ]
Subtotal (95% CI) 73 73 100.0 % 1.40 [ 0.47, 4.21 ]
Total events: 7 (FPO + CTG), 5 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
3 Gestation from 28 weeks, FBS not required prior to study entry
Klauser 2005 34/150 41/177 100.0 % 0.98 [ 0.66, 1.46 ]
Subtotal (95% CI) 150 177 100.0 % 0.98 [ 0.66, 1.46 ]
Total events: 34 (FPO + CTG), 41 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.92)
4 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 490/2629 521/2712 100.0 % 0.97 [ 0.87, 1.08 ]
Subtotal (95% CI) 2629 2712 100.0 % 0.97 [ 0.87, 1.08 ]
Total events: 490 (FPO + CTG), 521 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
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Analysis 2.7. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 7
Operative delivery (caesarean section, forceps, vacuum extraction) for all indications.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 7 Operative delivery (caesarean section, forceps, vacuum extraction) for all indications
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 34 weeks, FBS not required prior to study entry
Garite 2000 267/508 247/502 25.6 % 1.07 [ 0.95, 1.21 ]
East 2006 224/305 209/295 27.4 % 1.04 [ 0.94, 1.15 ]
Caliskan 2009 23/114 34/116 6.9 % 0.69 [ 0.43, 1.09 ]
Subtotal (95% CI) 927 913 59.9 % 1.03 [ 0.92, 1.15 ]
Total events: 514 (FPO + CTG), 490 (CTG only)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.30, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 0.45 (P = 0.65)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 25/73 49/73 10.2 % 0.51 [ 0.36, 0.73 ]
Subtotal (95% CI) 73 73 10.2 % 0.51 [ 0.36, 0.73 ]
Total events: 25 (FPO + CTG), 49 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 3.70 (P = 0.00021)
3 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 1072/2629 1147/2712 29.9 % 0.96 [ 0.90, 1.03 ]
Subtotal (95% CI) 2629 2712 29.9 % 0.96 [ 0.90, 1.03 ]
Total events: 1072 (FPO + CTG), 1147 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 3629 3698 100.0 % 0.92 [ 0.81, 1.06 ]
Total events: 1611 (FPO + CTG), 1686 (CTG only)
Heterogeneity: Tau2 = 0.02; Chi2 = 18.80, df = 4 (P = 0.00086); I2 =79%
Test for overall effect: Z = 1.12 (P = 0.26)
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Analysis 2.8. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 8
Operative delivery (caesarean section, forceps, vacuum) for nonreassuring fetal status.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 8 Operative delivery (caesarean section, forceps, vacuum) for nonreassuring fetal status
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 78/508 108/502 42.8 % 0.71 [ 0.55, 0.93 ]
East 2006 76/305 95/295 43.0 % 0.77 [ 0.60, 1.00 ]
Subtotal (95% CI) 813 797 85.9 % 0.74 [ 0.62, 0.89 ]
Total events: 154 (FPO + CTG), 203 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.16 (P = 0.0016)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 2/73 37/73 14.1 % 0.05 [ 0.01, 0.22 ]
Subtotal (95% CI) 73 73 14.1 % 0.05 [ 0.01, 0.22 ]
Total events: 2 (FPO + CTG), 37 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 4.13 (P = 0.000037)
Total (95% CI) 886 870 100.0 % 0.51 [ 0.27, 0.96 ]
Total events: 156 (FPO + CTG), 240 (CTG only)
Heterogeneity: Tau2 = 0.22; Chi2 = 15.12, df = 2 (P = 0.00052); I2 =87%
Test for overall effect: Z = 2.09 (P = 0.036)
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Analysis 2.9. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 9 Use
of intrapartum antibiotics.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 9 Use of intrapartum antibiotics
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
East 2006 110/305 98/295 55.5 % 1.09 [ 0.87, 1.35 ]
Subtotal (95% CI) 305 295 55.5 % 1.09 [ 0.87, 1.35 ]
Total events: 110 (FPO + CTG), 98 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
2 Gestation from 36 weeks, FBS required prior to study entry
Kuhnert 2004 15/73 29/73 44.5 % 0.52 [ 0.30, 0.88 ]
Subtotal (95% CI) 73 73 44.5 % 0.52 [ 0.30, 0.88 ]
Total events: 15 (FPO + CTG), 29 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
Total (95% CI) 378 368 100.0 % 0.78 [ 0.38, 1.61 ]
Total events: 125 (FPO + CTG), 127 (CTG only)
Heterogeneity: Tau2 = 0.23; Chi2 = 6.39, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.67 (P = 0.50)
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Analysis 2.10. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 10
Overall antibiotic use.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 10 Overall antibiotic use
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 15/73 29/73 100.0 % 0.52 [ 0.30, 0.88 ]
Total (95% CI) 73 73 100.0 % 0.52 [ 0.30, 0.88 ]
Total events: 15 (FPO + CTG), 29 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
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Analysis 2.11. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 11
Intrapartum haemorrhage.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 11 Intrapartum haemorrhage
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 1/508 0/502 9.7 % 2.96 [ 0.12, 72.60 ]
East 2006 7/305 5/295 77.1 % 1.35 [ 0.43, 4.22 ]
Subtotal (95% CI) 813 797 86.9 % 1.48 [ 0.51, 4.31 ]
Total events: 8 (FPO + CTG), 5 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 1/73 1/73 13.1 % 1.00 [ 0.06, 15.69 ]
Subtotal (95% CI) 73 73 13.1 % 1.00 [ 0.06, 15.69 ]
Total events: 1 (FPO + CTG), 1 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 886 870 100.0 % 1.40 [ 0.52, 3.81 ]
Total events: 9 (FPO + CTG), 6 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
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Analysis 2.12. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 12
Postpartum haemorrhage.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 12 Postpartum haemorrhage
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 19/637 17/552 59.0 % 0.97 [ 0.51, 1.84 ]
East 2006 12/305 4/295 41.0 % 2.90 [ 0.95, 8.89 ]
Subtotal (95% CI) 942 847 100.0 % 1.52 [ 0.53, 4.39 ]
Total events: 31 (FPO + CTG), 21 (CTG only)
Heterogeneity: Tau2 = 0.39; Chi2 = 2.79, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 920 100.0 % 1.52 [ 0.53, 4.39 ]
Total events: 31 (FPO + CTG), 21 (CTG only)
Heterogeneity: Tau2 = 0.39; Chi2 = 2.79, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.77 (P = 0.44)
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Analysis 2.13. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 13
Chorioamnionitis.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 13 Chorioamnionitis
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 2/73 3/73 0.8 % 0.67 [ 0.11, 3.87 ]
Subtotal (95% CI) 73 73 0.8 % 0.67 [ 0.11, 3.87 ]
Total events: 2 (FPO + CTG), 3 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 282/2629 291/2712 99.2 % 1.00 [ 0.86, 1.17 ]
Subtotal (95% CI) 2629 2712 99.2 % 1.00 [ 0.86, 1.17 ]
Total events: 282 (FPO + CTG), 291 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Total (95% CI) 2702 2785 100.0 % 1.00 [ 0.85, 1.16 ]
Total events: 284 (FPO + CTG), 294 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
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Analysis 2.14. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 14
Endometritis.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 14 Endometritis
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 18/637 16/552 12.3 % 0.97 [ 0.50, 1.89 ]
East 2006 4/305 1/295 1.1 % 3.87 [ 0.43, 34.41 ]
Subtotal (95% CI) 942 847 13.5 % 1.29 [ 0.43, 3.88 ]
Total events: 22 (FPO + CTG), 17 (CTG only)
Heterogeneity: Tau2 = 0.28; Chi2 = 1.41, df = 1 (P = 0.23); I2 =29%
Test for overall effect: Z = 0.46 (P = 0.64)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 114/2629 120/2712 86.5 % 0.98 [ 0.76, 1.26 ]
Subtotal (95% CI) 2629 2712 86.5 % 0.98 [ 0.76, 1.26 ]
Total events: 114 (FPO + CTG), 120 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Total (95% CI) 3644 3632 100.0 % 0.99 [ 0.79, 1.26 ]
Total events: 136 (FPO + CTG), 137 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.50, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.96)
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Analysis 2.15. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 15
Uterine rupture.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 15 Uterine rupture
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 2/637 2/552 100.0 % 0.87 [ 0.12, 6.13 ]
East 2006 0/305 0/295 Not estimable
Subtotal (95% CI) 942 847 100.0 % 0.87 [ 0.12, 6.13 ]
Total events: 2 (FPO + CTG), 2 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 920 100.0 % 0.87 [ 0.12, 6.13 ]
Total events: 2 (FPO + CTG), 2 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
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Analysis 2.16. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 16
Length of hospital stay (days).
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 16 Length of hospital stay (days)
Study or subgroup FPO + CTG CTG only
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Gestation from 36 weeks, FBS not required prior to study entry
East 2006 305 4.4 (1.86) 295 4.46 (1.85) 82.7 % -0.06 [ -0.36, 0.24 ]
Subtotal (95% CI) 305 295 82.7 % -0.06 [ -0.36, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 73 4 (2) 73 4 (2) 17.3 % 0.0 [ -0.65, 0.65 ]
Subtotal (95% CI) 73 73 17.3 % 0.0 [ -0.65, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 378 368 100.0 % -0.05 [ -0.32, 0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
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Analysis 2.17. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 17
Satisfaction with labour.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 17 Satisfaction with labour
Study or subgroup FPO + CTG CTG only
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Gestation from 36 weeks, FBS not required prior to study entry
East 2006 233 9.3 (1.91) 215 9.1 (1.99) 100.0 % 0.20 [ -0.16, 0.56 ]
Total (95% CI) 233 215 100.0 % 0.20 [ -0.16, 0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 2.18. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 18
Satisfaction with fetal monitoring in labour.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 18 Satisfaction with fetal monitoring in labour
Study or subgroup FPO + CTG CTG only
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Gestation from 36 weeks, FBS not required prior to study entry
East 2006 233 12.6 (2.38) 215 12.2 (2.43) 100.0 % 0.40 [ -0.05, 0.85 ]
Total (95% CI) 233 215 100.0 % 0.40 [ -0.05, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.079)
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Analysis 2.19. Comparison 2 Secondary outcomes: maternal: FPO + CTG versus CTG only, Outcome 19
Death.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 2 Secondary outcomes: maternal: FPO + CTG versus CTG only
Outcome: 19 Death
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 0/637 0/552 Not estimable
East 2006 0/305 0/295 Not estimable
Subtotal (95% CI) 942 847 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 920 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 3.20. Comparison 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only, Outcome
20 Skin trauma.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome: 20 Skin trauma
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
East 2006 3/305 4/295 100.0 % 0.73 [ 0.16, 3.21 ]
Subtotal (95% CI) 305 295 100.0 % 0.73 [ 0.16, 3.21 ]
Total events: 3 (FPO + CTG), 4 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 378 368 100.0 % 0.73 [ 0.16, 3.21 ]
Total events: 3 (FPO + CTG), 4 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
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Analysis 3.21. Comparison 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only, Outcome
21 Apgar score less than 4 at 5 minutes.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome: 21 Apgar score less than 4 at 5 minutes
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 1/637 0/552 15.8 % 2.60 [ 0.11, 63.70 ]
East 2006 0/305 0/295 Not estimable
Subtotal (95% CI) 942 847 15.8 % 2.60 [ 0.11, 63.70 ]
Total events: 1 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 6/2629 3/2712 84.2 % 2.06 [ 0.52, 8.24 ]
Subtotal (95% CI) 2629 2712 84.2 % 2.06 [ 0.52, 8.24 ]
Total events: 6 (FPO + CTG), 3 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 3644 3632 100.0 % 2.14 [ 0.60, 7.63 ]
Total events: 7 (FPO + CTG), 3 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
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Analysis 3.22. Comparison 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only, Outcome
22 Apgar score less than 7 at 5 minutes.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome: 22 Apgar score less than 7 at 5 minutes
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 34 weeks, FBS not required prior to study entry
Garite 2000 14/637 19/552 59.0 % 0.64 [ 0.32, 1.26 ]
East 2006 5/305 6/295 19.8 % 0.81 [ 0.25, 2.61 ]
Caliskan 2009 1/114 2/116 4.8 % 0.51 [ 0.05, 5.53 ]
Subtotal (95% CI) 1056 963 83.6 % 0.67 [ 0.38, 1.18 ]
Total events: 20 (FPO + CTG), 27 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
2 Gestation from 36 weeks, FBS required prior to study entry
Kuhnert 2004 1/73 0/73 2.7 % 3.00 [ 0.12, 72.45 ]
Subtotal (95% CI) 73 73 2.7 % 3.00 [ 0.12, 72.45 ]
Total events: 1 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 Gestation from 28 weeks, FBS not required prior to study entry
Klauser 2005 3/150 5/177 13.7 % 0.71 [ 0.17, 2.91 ]
Subtotal (95% CI) 150 177 13.7 % 0.71 [ 0.17, 2.91 ]
Total events: 3 (FPO + CTG), 5 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 1279 1213 100.0 % 0.70 [ 0.41, 1.18 ]
Total events: 24 (FPO + CTG), 32 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.00, df = 4 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
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Analysis 3.23. Comparison 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only, Outcome
23 Umbilical arterial pH less than 7.10.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome: 23 Umbilical arterial pH less than 7.10
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 32/637 27/552 44.9 % 1.03 [ 0.62, 1.69 ]
East 2006 13/272 12/240 29.1 % 0.96 [ 0.44, 2.05 ]
Subtotal (95% CI) 909 792 74.0 % 1.01 [ 0.66, 1.53 ]
Total events: 45 (FPO + CTG), 39 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 1/73 6/73 5.9 % 0.17 [ 0.02, 1.35 ]
Subtotal (95% CI) 73 73 5.9 % 0.17 [ 0.02, 1.35 ]
Total events: 1 (FPO + CTG), 6 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.093)
3 Gestation from 28 weeks, FBS not required prior to study entry
Klauser 2005 5/150 13/177 20.1 % 0.45 [ 0.17, 1.24 ]
Subtotal (95% CI) 150 177 20.1 % 0.45 [ 0.17, 1.24 ]
Total events: 5 (FPO + CTG), 13 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 1132 1042 100.0 % 0.77 [ 0.45, 1.30 ]
Total events: 51 (FPO + CTG), 58 (CTG only)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.51, df = 3 (P = 0.21); I2 =33%
Test for overall effect: Z = 0.98 (P = 0.33)
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Analysis 3.24. Comparison 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only, Outcome
24 Umbilical arterial base excess less than -12.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome: 24 Umbilical arterial base excess less than -12
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 13/637 13/552 57.6 % 0.87 [ 0.41, 1.85 ]
East 2006 10/257 6/224 33.5 % 1.45 [ 0.54, 3.93 ]
Subtotal (95% CI) 894 776 91.1 % 1.05 [ 0.57, 1.92 ]
Total events: 23 (FPO + CTG), 19 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 2/73 2/73 8.9 % 1.00 [ 0.14, 6.91 ]
Subtotal (95% CI) 73 73 8.9 % 1.00 [ 0.14, 6.91 ]
Total events: 2 (FPO + CTG), 2 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 967 849 100.0 % 1.04 [ 0.59, 1.86 ]
Total events: 25 (FPO + CTG), 21 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
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Analysis 3.25. Comparison 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only, Outcome
25 Admission to neonatal intensive care unit.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome: 25 Admission to neonatal intensive care unit
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 34 weeks, FBS not required prior to study entry
Garite 2000 104/637 79/552 35.8 % 1.14 [ 0.87, 1.49 ]
East 2006 9/305 11/295 3.5 % 0.79 [ 0.33, 1.88 ]
Caliskan 2009 5/114 6/116 1.9 % 0.85 [ 0.27, 2.70 ]
Subtotal (95% CI) 1056 963 41.2 % 1.09 [ 0.85, 1.40 ]
Total events: 118 (FPO + CTG), 96 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 5/73 5/73 1.8 % 1.00 [ 0.30, 3.31 ]
Subtotal (95% CI) 73 73 1.8 % 1.00 [ 0.30, 3.31 ]
Total events: 5 (FPO + CTG), 5 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Gestation from 28 weeks, FBS not required prior to study entry
Klauser 2005 20/150 25/177 8.7 % 0.94 [ 0.55, 1.63 ]
Subtotal (95% CI) 150 177 8.7 % 0.94 [ 0.55, 1.63 ]
Total events: 20 (FPO + CTG), 25 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
4 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 126/2629 147/2712 48.3 % 0.88 [ 0.70, 1.11 ]
Subtotal (95% CI) 2629 2712 48.3 % 0.88 [ 0.70, 1.11 ]
Total events: 126 (FPO + CTG), 147 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 3908 3925 100.0 % 0.97 [ 0.83, 1.14 ]
Total events: 269 (FPO + CTG), 273 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.29, df = 5 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
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Analysis 3.26. Comparison 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only, Outcome
26 Length of hospital stay (days).
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome: 26 Length of hospital stay (days)
Study or subgroup FPO + CTG CTG only
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Gestation from 36 weeks, FBS not required prior to study entry
East 2006 305 3.74 (2.35) 295 3.74 (1.74) 49.1 % 0.0 [ -0.33, 0.33 ]
Subtotal (95% CI) 305 295 49.1 % 0.0 [ -0.33, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 73 2 (1) 73 2 (1) 50.9 % 0.0 [ -0.32, 0.32 ]
Subtotal (95% CI) 73 73 50.9 % 0.0 [ -0.32, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 378 368 100.0 % 0.0 [ -0.23, 0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 3.27. Comparison 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only, Outcome
27 Death.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome: 27 Death
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 3/637 2/552 61.6 % 1.30 [ 0.22, 7.75 ]
East 2006 0/305 1/295 19.2 % 0.32 [ 0.01, 7.88 ]
Subtotal (95% CI) 942 847 80.8 % 0.93 [ 0.20, 4.44 ]
Total events: 3 (FPO + CTG), 3 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 0/2629 1/2712 19.2 % 0.34 [ 0.01, 8.44 ]
Subtotal (95% CI) 2629 2712 19.2 % 0.34 [ 0.01, 8.44 ]
Total events: 0 (FPO + CTG), 1 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Total (95% CI) 3644 3632 100.0 % 0.77 [ 0.19, 3.13 ]
Total events: 3 (FPO + CTG), 4 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.86, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
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Analysis 3.28. Comparison 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only, Outcome
28 Death, hypoxic-ischaemic encephalopathy, or both.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome: 28 Death, hypoxic-ischaemic encephalopathy, or both
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 3/637 2/552 60.3 % 1.30 [ 0.22, 7.75 ]
East 2006 0/305 1/295 18.8 % 0.32 [ 0.01, 7.88 ]
Subtotal (95% CI) 942 847 79.1 % 0.93 [ 0.20, 4.44 ]
Total events: 3 (FPO + CTG), 3 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Gestation from 36 weeks, FBS required prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Gestation from 36 weeks, nonreassuring fetal status not required prior to study entry
Bloom 2006 0/2629 2/2712 20.9 % 0.21 [ 0.01, 4.30 ]
Subtotal (95% CI) 2629 2712 20.9 % 0.21 [ 0.01, 4.30 ]
Total events: 0 (FPO + CTG), 2 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 3644 3632 100.0 % 0.68 [ 0.17, 2.73 ]
Total events: 3 (FPO + CTG), 5 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
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Analysis 3.29. Comparison 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only, Outcome
29 Death, seizures, or both.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome: 29 Death, seizures, or both
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 3/637 3/552 75.0 % 0.87 [ 0.18, 4.28 ]
East 2006 1/305 1/295 25.0 % 0.97 [ 0.06, 15.39 ]
Subtotal (95% CI) 942 847 100.0 % 0.89 [ 0.22, 3.55 ]
Total events: 4 (FPO + CTG), 4 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 920 100.0 % 0.89 [ 0.22, 3.55 ]
Total events: 4 (FPO + CTG), 4 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
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Analysis 3.30. Comparison 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only, Outcome
30 Death, long-term neurodevelopmental problem, or both.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 3 Secondary outcomes: fetal/neonatal: FPO + CTG versus CTG only
Outcome: 30 Death, long-term neurodevelopmental problem, or both
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gestation from 36 weeks, FBS not required prior to study entry
Garite 2000 3/637 2/552 76.2 % 1.30 [ 0.22, 7.75 ]
East 2006 0/305 1/295 23.8 % 0.32 [ 0.01, 7.88 ]
Subtotal (95% CI) 942 847 100.0 % 0.93 [ 0.20, 4.44 ]
Total events: 3 (FPO + CTG), 3 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Gestation from 36 weeks, FBS prior to study entry
Kuhnert 2004 0/73 0/73 Not estimable
Subtotal (95% CI) 73 73 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 920 100.0 % 0.93 [ 0.20, 4.44 ]
Total events: 3 (FPO + CTG), 3 (CTG only)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
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Analysis 4.1. Comparison 4 Subgroup: fetal blood sampling: primary outcomes, Outcome 1 Caesarean
section.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 4 Subgroup: fetal blood sampling: primary outcomes
Outcome: 1 Caesarean section
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
East 2006 27/41 84/157 100.0 % 1.23 [ 0.94, 1.60 ]
Total (95% CI) 41 157 100.0 % 1.23 [ 0.94, 1.60 ]
Total events: 27 (FPO + CTG), 84 (CTG only)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
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Analysis 4.2. Comparison 4 Subgroup: fetal blood sampling: primary outcomes, Outcome 2 Neonatal
seizures.
Review: Fetal pulse oximetry for fetal assessment in labour
Comparison: 4 Subgroup: fetal blood sampling: primary outcomes
Outcome: 2 Neonatal seizures
Study or subgroup FPO + CTG CTG only Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
East 2006 0/41 0/157 Not estimable
Total (95% CI) 41 157 Not estimable
Total events: 0 (FPO + CTG), 0 (CTG only)
Heterogeneity: not applicable
Test for overall effect: not applicable
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A P P E N D I C E S
Appendix 1. Methods used to assess trials included in previous versions of this review
The following methods were used to assess Bloom 2006; East 2006; Garite 2000; Klauser 2005; Kuhnert 2004.
We used the standard methods of the Cochrane Collaboration as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2005). At least two authors (Chris East (CE), Fung Yee Chan (FYC), Lisa Begg (LB), Paul Colditz (PC))
assessed trials under consideration for appropriateness of inclusion and methodological quality without consideration of their results.
LB assessed, in particular, the quality and findings of the trials for which the remaining authors were co-investigators (East 2006). There
were no differences of opinion requiring resolution by an alternative author. Blinding of trial authorship was not undertaken.
Assessment of trial quality
We considered four major sources of potential bias and methods or avoidance of these biases when assessing trial quality: (1) selection
bias - allocation concealment; (2) performance bias - blinding of intervention; (3) attrition bias - completeness of follow up; (4)
detection bias - blinding of outcome assessment. The quality assessment was based on a systematic assessment of the opportunity for
each of these biases to arise.
We assigned a quality rating for allocation concealment, using the criteria outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2005): (A) adequate; (B) unclear; (C) inadequate; or (D) not used. A quality rating of (A) = yes; (B) = cannot
tell; or (C) = no, was assigned to the other quality components (blinding of intervention, completeness of follow up and blinding of
outcome assessment).
We made an a priori decision to exclude trials where outcome data were unavailable for more than 20% of participants.
Data management
We sought additional information from the authors of three trials (see ’Characteristics of included studies’ table).
At least two independent authors (CE, FYC, LB, PC) performed data extraction and any disagreements were to have been resolved by
discussion with an alternative author. There were no disagreements. Analyses were performed on an intention-to-treat basis.
We reported mean differences (and 95% confidence intervals) for continuous variables with reported data. For categorical outcomes,
the relative risks (and 95% confidence intervals) were reported.
Data analysis
The differences in entry criteria for the reported studiesmade combined statistical analysis problematic.We addressed this by considering
the following analyses:
(A) nonreassuring fetal heart rate prior to study entry:
(i) gestation from 36 weeks, fetal blood sampling (fetal blood sampling) not required prior to study entry;
(ii) gestation from 36 weeks, fetal blood sampling prior to study entry;
(iii) gestation from 28 weeks, fetal blood sampling not required prior to study entry; and
(B) gestation from 36 weeks, nonreassuring fetal status not required prior to study entry.
Sensitivity analyses were conducted to evaluate the effect of trial quality: separate analysis of different types of studies within each
outcome allowed inclusion of all identified studies, regardless of trial quality. Heterogeneity was addressed by the use of separate analyses
of different types of studies within each analysis and random-effects modelling.
We planned subgroup analyses, to be conducted separately for singleton and multiple pregnancies as data permitted, for the primary
outcomes as follows.
Fetal pulse oximetry compared with:
(i) fetal heart rate monitoring by:
• intermittent auscultation;
• intermittent cardiotocography;
• continuous cardiotocography;
• continuous cardiotocography and fetal scalp stimulation;
• continuous cardiotocography and fetal electrocardiogram (ECG) analysis (ST segment);
• continuous cardiotocography and fetal ECG analysis (PR interval); and
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(ii) fetal blood sampling for blood gas analysis.
Several trials indicated that fetal blood sampling was performed (East 2006; Garite 2000; Kuhnert 2004). However, data were only
available to allow for one of these to be included in a subgroup analysis (East 2006). None of the remaining subgroup analyses were
conducted, as we were unable to identify trials that addressed these questions.
Appendix 2. Search strategies
Authors searchedMEDLINE (1994 toMay 2010), EMBASE (1994 toMay 2010) and Current Contents (1994 toMay 2010): searches
were conducted from 1994 onwards as pulse oximetry technology calibrated for the fetal environment has only been available since
1994. Searches were conducted using search terms: (labour OR labor OR intrapartum) AND (oximetry OR pulse oximetry OR oxygen
saturation) AND (clinical trial phase 1 OR clinical trial phase II OR clinical trial phase III OR controlled clinical trial OR randomized
controlled trial OR randomised controlled trial) AND (fetal distress OR fetal heart OR fetal monitoring OR nonreassuring OR non-
reassuring).
F E E D B A C K
Thornton, July 2006
Summary
The abstract states ’Use of fetal pulse oximetry with CTG decreased operative delivery (caesarean section, forceps, vacuum) for
nonreassuring fetal status (RR 0.71, 95% CI 0.55 to 0.93) compared with CTG alone.’
The results text also states ’There was a statistically significant decrease in operative delivery (caesarean section, forceps or vacuum birth)
for nonreassuring fetal status (RR 0.71, 95% CI 0.55 to 0.93).
But the results tables show a Relative Risk (Fixed) 95% CI 1.07 [0.95, 1.21]. Am I missing something, or has there been a mistake?
(Summary of comment from Jim Thornton, July 2006)
Reply
The data in the text are correct. The data quoted from the results table refer to the outcome ’operative delivery (caesarean section,
forceps or vacuum birth)’, which is for all indications; the data quoted in the text are for ’operative delivery (caesarean section, forceps
or vacuum birth) for nonreassuring fetal status’ and are correct.
To help clarify this, the outcome in the review now includes the wording ’for all indications’.
(Summary of response from Christine East, November 2006)
Contributors
Feedback: Jim Thornton
Reply: Christine East
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WH A T ’ S N E W
Last assessed as up-to-date: 18 May 2010.
Date Event Description
11 September 2012 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 1, 2003
Review first published: Issue 4, 2004
Date Event Description
31 May 2010 New search has been performed One new trial added to the review. This did not change
the conclusions of the review. Prof FY Chan removed
from authorship (deceased 2007) although previous
input gratefully recognised
1 October 2009 Amended Search updated. Five reports added to Studies await-
ing classification (Caliskan 2009a; East 2006b; Prieto
2008; Rouse 2008; Rouse 2009).
10 November 2008 Amended Contact details updated.
18 February 2008 Amended Converted to new review format.
17 January 2007 New citation required and conclusions have changed Search updated in November 2006. We identified and
included four new trials (Bloom 2006; East 2006;
Klauser 2005; Kuhnert 2004).
The original version of this review concluded that the
addition of fetal pulse oximetry to cardiotocography
decreased the caesarean section and operative delivery
rates for nonreassuring fetal status, with no difference
in overall caesarean section rates. The addition of the
four new trials confirmed these conclusionswhen non-
reassuring fetal status was identified prior to study en-
try. When nonreassuring fetal status was not present
prior to study entry, knowledge of fetal pulse oximetry
values made no difference to caesarean section rates for
nonreassuring fetal status or for all indications
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C O N T R I B U T I O N S O F A U T H O R S
C East compiled the protocol and original review with input from all co-authors. L Begg joined the authorship in 2006 for the 2007
update. FY Chan died in 2007 and has not been replaced on the authorship in the 2010 update.
C East, FY Chan (to 2007), P Colditz and/or L Begg reviewed the articles for consideration of inclusion/exclusion and abstracted data
for the review. In particular, L Begg, who was not a co-investigator on the trial by the other three authors, reviewed that trial for quality
and suitability for inclusion in this review.
D E C L A R A T I O N S O F I N T E R E S T
Three authors (C East, FY Chan, P Colditz) were chief investigators in the Australian multicentre randomised controlled trial of fetal
intrapartum pulse oximetry (East 2006). That trial was supported in part by a research grant and equipment loan from Nellcor Inc,
manufacturers of a fetal pulse oximetry system. An additional co-author who was not an investigator in that trial, L Begg, joined the
review team to evaluate that trial for incorporation in the 2007 update of the review.
S O U R C E S O F S U P P O R T
Internal sources
• Perinatal Research Centre, The University of Queensland, Royal Brisbane and Women’s Hospital, Herston, Queensland,
Australia.
• Department of Obstetrics and Gynaecology, University of Melbourne, Australia.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This update (May 2010) incorporates the current standard methods used by the Pregnancy and Childbirth Group, which have been
modified since the original protocol was published (East 2003). See Appendix 1 for the methods used in earlier versions of this review,
which aligned with those published in the protocol.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Cardiotocography; Cesarean Section; Delivery,Obstetric [statistics & numerical data]; FetalMonitoring [∗methods];Oximetry [adverse
effects; ∗methods]
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MeSH check words
Female; Humans; Pregnancy
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